| Revenue - Collaboration Agreement - The GSK Collaboration and License Agreement (Details) | Mar. 31, 2022  USD ($) | 
|---|---|
| Collaboration and License Agreement | |
| Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements | $ 386,381,000 | 
| GSK Collaboration And License Agreement | |
| Collaboration and License Agreement | |
| Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements | $ 7,214,000 | 
| X | ||||||||||
| 
- Definition ASC 606-10-50-13a: The aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. No definition available. 
 | 
| X | ||||||||||
| 
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available. 
 | 
| X | ||||||||||
| 
- Details 
 |